Business Wire

Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors

17.2.2021 16:03:00 EET | Business Wire | Press release

Share

Abiomed (NASDAQ: ABMD) announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors, effective immediately. Dr. Rolle will serve as a member of the Governance and Nominating Committee and Regulatory and Compliance Committee of the board. With the appointment of Dr. Rolle, the board now comprises of eight active directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005546/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr. Myron Rolle joins the Abiomed Board of Directors (Photo: Business Wire)

Dr. Rolle is a neurosurgeon, Rhodes scholar, and former professional football player in the National Football League. He developed and published the Rolle Scoring System, a public health rating scale used to determine a developing country’s governance around helmet safety to prevent traumatic brain injury. He has been recognized by the Congress of Neurological Surgeons for demonstrating the best operative technique in the reconstruction of upper extremity motor function using intercostal nerve transfers after a traumatic brachial plexus injury. Dr. Rolle is the chairman of the Myron L. Rolle Foundation, which provides health, wellness and education services to underserved populations in the United States and the Bahamas. He is the founder of the CARICOM Neurosurgical Initiative, a capacity-building and health system-strengthening project for improved neurosurgical care in the Caribbean.

“As someone practicing medicine today, Dr. Rolle understands the role of medical technology in improving outcomes for patients,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “Dr. Rolle’s experience as a Rhodes scholar, professional athlete and physician will bring unique perspective to our board. His non-profit leadership in addressing health inequities will help advance Abiomed’s initiative to partner with hospitals in inner cities to reduce health disparities.”

“Dr. Rolle’s appointment reflects Abiomed’s commitment to ensuring we have a broad mix of skills and viewpoints on the board. We look forward to benefiting from Dr. Rolle’s experience as we continue to grow the company,” said Dorothy E. Puhy, lead independent director of the Abiomed Board of Directors and former executive vice president, chief operating officer and assistant treasurer at Dana Farber Cancer Institute.

“I am excited to join the Abiomed Board of Directors and contribute to the company’s long-term growth and success. Abiomed is a company I truly believe in. Its patients first mission aligns with my professional and personal desire to make a positive impact on the lives of others,” said Dr. Rolle. “I look forward to working with Abiomed management and my fellow directors to be a valuable contributor to the board, to further improve outcomes for patients, and to help provide access to Abiomed’s life-saving technology to more people.”

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sarah Karr
Communications Manager
978-882-8211
skarr@abiomed.com

Investor:
Todd Trapp
Vice President and Chief Financial Officer
(978) 646-1680
ttrapp@abiomed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release

Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul

Klarna Submits Application for U.S. Banking License6.7.2026 15:30:00 EEST | Press release

Klarna (NYSE: KLAR), the global digital bank and flexible payments provider, today announced it has submitted applications to the Utah Department of Financial Institutions and the Federal Deposit Insurance Corporation (FDIC) to establish Klarna Bank USA, a proposed Utah-chartered industrial bank. Klarna has operated as a licensed bank in Europe since 2017 and serves U.S. customers through valued partner banks. Since 2019, Klarna has provided Americans with access to over $91.3 billion in responsible credit, saving them more than $5.1 billion in interest compared to revolving credit card debt. Today, 30 million Americans use Klarna each year, and hundreds of thousands of merchants rely on Klarna to grow their businesses. "Banking is built on trust," said Sebastian Siemiatkowski, co-founder and CEO of Klarna. "We've seen firsthand the appetite for a fairer, more transparent approach in the U.S., and our own banking license is the natural next step, giving customers tools to borrow respon

IQM Quantum Computers Acquires Assets of Quantistry GmbH to Bridge the Gap Between Quantum Algorithms and Solutions for Industrial Enterprises6.7.2026 15:00:00 EEST | Press release

IQM Quantum Computers (Nasdaq: IQMX) (“IQM”, “IQM Quantum Computers” or the “Company”), a global leader in full-stack superconducting quantum computers, has acquired selected assets of Quantistry GmbH, a Berlin-based developer of cloud-native simulation workflow platform for automotive, aerospace, chemical, materials and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706448170/en/ IQM Quantum Computers Acquires Assets of Quantistry GmbH to bridge the gap between Quantum Algorithms and Solutions for Industrial Enterprises The acquired assets include proprietary software applications, algorithms, and intellectual property. IQM will also retain Quantistry's core technical, quantum chemistry, and software engineering talent, ensuring seamless continuity and rapid platform integration. The transaction completed recently, concurrently with IQM's business combination with Real Asset Acquisition Corp. (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye